Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Company News

Opexa, Merck KGaA deal

May 18, 2015 7:00 AM UTC

In March, the partners amended a February 2013 deal granting Merck’s Merck Serono division an exclusive option to license ex-Japan rights to develop and commercialize the biotech’s Tcelna imilecleucel-T to treat multiple sclerosis. Under the amendment, Opexa will provide Merck Serono with a detailed pre-Phase III plan by year end 2016. Merck’s option will expire 60 days after the joint steering committee approves the pre-Phase III plan. ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article